Possible molecular and paracrine involvement underlying the pathogenesis of COVID-19 cardiovascular complications.
angiotensin-converting enzyme 2
cardiomyocytes
coronavirus disease 2019
drug repurposing
endothelium
paracrine effect of cytokines
Journal
Cardiovascular endocrinology & metabolism
ISSN: 2574-0954
Titre abrégé: Cardiovasc Endocrinol Metab
Pays: United States
ID NLM: 101730894
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
06
04
2020
accepted:
14
04
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
18
8
2020
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) has been declared a pandemic on 11 March 2020 by the WHO. Despite being mainly a respiratory virus, cardiac complications have been described. These range from sudden cardiac death to subtle diastolic dysfunction after recovery from COVID-19. The commonest cardiac presentation to date is acute heart failure resulting from biventricular or left ventricular hypokinesis and elevation of cardiac troponins. It has been shown that COVID-19 downregulates angiotensin-converting enzyme-2, which has protective effects on the endothelium and cardiomyocytes. It has also been proven that COVID-19 induces a state of hypercytokinaemia, some cytokines such as interleukin-1 and interleukin-6 have an injurious effect on the myocardium and endothelium, respectively. Such pathogenic mechanisms might play a crucial role in induction of cardiomyocyte injury and impaired myocardial perfusion probably through coronary endothelial dysfunction. The understanding and linking of such mechanisms might help in tailoring drug repurposing for treatment or prophylaxis of COVID-19 cardiovascular complications.
Identifiants
pubmed: 32803146
doi: 10.1097/XCE.0000000000000207
pmc: PMC7410028
doi:
Types de publication
Editorial
Langues
eng
Pagination
121-124Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
J Am Coll Cardiol. 1995 Oct;26(4):1016-21
pubmed: 7560594
J Mol Cell Cardiol. 2002 Nov;34(11):1443-53
pubmed: 12431443
Discoveries (Craiova). 2015 Jan-Mar;3(1):
pubmed: 26273700
Eur Heart J. 2020 Jun 7;41(22):2130
pubmed: 32227076
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Immun Inflamm Dis. 2017 Sep;5(3):373-379
pubmed: 28548248
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Postgrad Med J. 2006 Feb;82(964):140-4
pubmed: 16461478
Eur Heart J. 2020 May 14;41(19):1798-1800
pubmed: 32186331
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):219-222
pubmed: 32164092
Curr Cardiol Rev. 2008 Aug;4(3):179-92
pubmed: 19936194
Circ Res. 2017 Sep 1;121(6):e22-e36
pubmed: 28743804
J Mol Med (Berl). 2016 Jan;94(1):37-49
pubmed: 26498282
Ann Saudi Med. 2016 Jan-Feb;36(1):78-80
pubmed: 26922692
Trop Med Int Health. 2020 Mar;25(3):278-280
pubmed: 32052514
Circ Res. 2000 Sep 1;87(5):E1-9
pubmed: 10969042
Eur Heart J. 2020 May 14;41(19):1861-1862
pubmed: 32267502
JAMA Cardiol. 2020 Mar 27;:
pubmed: 32219357
JAMA. 2020 Feb 7;:
pubmed: 32031570
Ann Intern Med. 2018 Dec 4;169(11):751-760
pubmed: 30398528
Circulation. 2003 Oct 14;108(15):1798-803
pubmed: 14504188
Arthritis Rheumatol. 2020 Feb;72(2):326-334
pubmed: 31513353
Zhonghua Jie He He Hu Xi Za Zhi. 2003 Oct;26(10):602-5
pubmed: 14633442
Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1377-84
pubmed: 18660448
Eur Heart J. 2020 May 7;41(18):1719
pubmed: 32232395